BusinessSelecta Biosciences Announces Preclinical Data Showing SVP-Rapamycin’s Potential Benefit in Treatment of Pompe DiseaseBy Nasdaq OMXFeb 15, 2017, 1:00 PM UTC
BusinessRecent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian CancerBy Nasdaq OMXFeb 9, 2017, 1:05 PM UTC
BusinessCombination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical TrialsBy Nasdaq OMXFeb 7, 2017, 9:40 PM UTC
BusinessSelecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine and Celiac Disease TreatmentBy Nasdaq OMXFeb 6, 2017, 1:00 PM UTC
BusinessSelecta Biosciences to Participate in Two Investor Conferences in FebruaryBy Nasdaq OMXJan 31, 2017, 1:00 PM UTC
BusinessAffimed Announces Proposed Public Offering of Common StockBy Nasdaq OMXJan 19, 2017, 9:02 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXDec 12, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXDec 6, 2016, 9:05 PM UTC
